RxDoctor Payments Data

Miguel Figueroa, MD

Pain Medicine · Natchez, MSNPI 1598703852

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by SPR Therapeutics, Inc at 27.2% of the total. That places this record below the midpoint for pain medicine clinicians in MS, where the typical reported total is $3,332.

$625in general payments, 2019–2025

Across 24 payments — averaging $26.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SPR Therapeutics, Inc$170
  • Collegium Pharmaceutical, Inc.$137
  • Boston Scientific$77
  • Averitas Pharma Inc.$50
  • Masimo Corporation$34
  • Pfizer$30
  • plus $126 from 7 others

What the payments were for

  • Food & beverage$625100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$625 in reported general payments places this provider in the 20th percentile of 48 pain medicine providers in Mississippi.

See all pain medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$81,296
Medicare patients
102
Services billed
1,269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide14$34,819
Xtampza ErOxycodone Myristate21$11,316
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen141$5,944
OxycontinOxycodone Hcl12$4,345
Lidocaine21$2,495
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen56$2,458
Morphine Sulfate ErMorphine Sulfate88$2,290
Gabapentin124$2,007
Fentanyl18$1,841
Oxycodone Hcl111$1,781
Diclofenac Sodium16$1,395
Tizanidine Hcl75$1,075
Pregabalin45$901
Methadone Hcl30$644
Duloxetine Hcl49$636

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$137$11,31621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 48 pain medicine providers in Mississippi.

Other pain medicine in Natchez

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →